US20120129853A1 - Methods of treatment using selective bcl-2 inhibitors - Google Patents
Methods of treatment using selective bcl-2 inhibitors Download PDFInfo
- Publication number
- US20120129853A1 US20120129853A1 US13/301,898 US201113301898A US2012129853A1 US 20120129853 A1 US20120129853 A1 US 20120129853A1 US 201113301898 A US201113301898 A US 201113301898A US 2012129853 A1 US2012129853 A1 US 2012129853A1
- Authority
- US
- United States
- Prior art keywords
- methyl
- piperazin
- chlorophenyl
- sulfonyl
- benzamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 CC.CC.[3*]OC1=CC(N2CCN(CC3=C(C4=CC=C(Cl)C=C4)CCCC3)CC2)=CC=C1C(=O)NS(=O)(=O)C1=CC=C(C)C(C)=C1 Chemical compound CC.CC.[3*]OC1=CC(N2CCN(CC3=C(C4=CC=C(Cl)C=C4)CCCC3)CC2)=CC=C1C(=O)NS(=O)(=O)C1=CC=C(C)C(C)=C1 0.000 description 6
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/301,898 US20120129853A1 (en) | 2010-11-23 | 2011-11-22 | Methods of treatment using selective bcl-2 inhibitors |
US14/535,070 US9345702B2 (en) | 2010-11-23 | 2014-11-06 | Methods of treatment using selective Bcl-2 inhibitors |
US15/136,582 US9872861B2 (en) | 2010-11-23 | 2016-04-22 | Methods of treatment using selective Bcl-2 inhibitors |
US15/838,605 US20180369250A1 (en) | 2010-11-23 | 2017-12-12 | Methods of treatment using selective bcl-2 inhibitors |
US16/415,515 US20200222413A1 (en) | 2010-11-23 | 2019-05-17 | Methods of treatment using selective bcl-2 inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41668910P | 2010-11-23 | 2010-11-23 | |
US13/301,898 US20120129853A1 (en) | 2010-11-23 | 2011-11-22 | Methods of treatment using selective bcl-2 inhibitors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/535,070 Continuation US9345702B2 (en) | 2010-11-23 | 2014-11-06 | Methods of treatment using selective Bcl-2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120129853A1 true US20120129853A1 (en) | 2012-05-24 |
Family
ID=45218888
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/301,898 Abandoned US20120129853A1 (en) | 2010-11-23 | 2011-11-22 | Methods of treatment using selective bcl-2 inhibitors |
US14/535,070 Active US9345702B2 (en) | 2010-11-23 | 2014-11-06 | Methods of treatment using selective Bcl-2 inhibitors |
US15/136,582 Active US9872861B2 (en) | 2010-11-23 | 2016-04-22 | Methods of treatment using selective Bcl-2 inhibitors |
US15/838,605 Abandoned US20180369250A1 (en) | 2010-11-23 | 2017-12-12 | Methods of treatment using selective bcl-2 inhibitors |
US16/415,515 Abandoned US20200222413A1 (en) | 2010-11-23 | 2019-05-17 | Methods of treatment using selective bcl-2 inhibitors |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/535,070 Active US9345702B2 (en) | 2010-11-23 | 2014-11-06 | Methods of treatment using selective Bcl-2 inhibitors |
US15/136,582 Active US9872861B2 (en) | 2010-11-23 | 2016-04-22 | Methods of treatment using selective Bcl-2 inhibitors |
US15/838,605 Abandoned US20180369250A1 (en) | 2010-11-23 | 2017-12-12 | Methods of treatment using selective bcl-2 inhibitors |
US16/415,515 Abandoned US20200222413A1 (en) | 2010-11-23 | 2019-05-17 | Methods of treatment using selective bcl-2 inhibitors |
Country Status (36)
Country | Link |
---|---|
US (5) | US20120129853A1 (ko) |
EP (2) | EP3028702B1 (ko) |
JP (2) | JP5876067B2 (ko) |
KR (3) | KR101841084B1 (ko) |
CN (2) | CN103402521B (ko) |
AR (1) | AR083946A1 (ko) |
AU (2) | AU2011332000B2 (ko) |
BR (1) | BR112013012854B1 (ko) |
CA (1) | CA2820618C (ko) |
CL (1) | CL2013001458A1 (ko) |
CR (1) | CR20130268A (ko) |
CY (1) | CY1118442T1 (ko) |
DK (1) | DK2642999T3 (ko) |
DO (1) | DOP2017000056A (ko) |
EC (1) | ECSP13012710A (ko) |
ES (2) | ES2603129T3 (ko) |
GT (1) | GT201300136A (ko) |
HR (1) | HRP20161762T1 (ko) |
HU (1) | HUE031267T2 (ko) |
IL (2) | IL226490A (ko) |
LT (1) | LT2642999T (ko) |
MX (1) | MX346201B (ko) |
MY (2) | MY191300A (ko) |
NZ (2) | NZ610746A (ko) |
PH (1) | PH12016500939A1 (ko) |
PL (1) | PL2642999T3 (ko) |
PT (1) | PT2642999T (ko) |
RS (1) | RS55545B1 (ko) |
RU (1) | RU2593231C2 (ko) |
SG (2) | SG190399A1 (ko) |
SI (1) | SI2642999T1 (ko) |
TW (2) | TWI535701B (ko) |
UA (2) | UA113157C2 (ko) |
UY (1) | UY33746A (ko) |
WO (1) | WO2012071374A1 (ko) |
ZA (1) | ZA201303589B (ko) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8722657B2 (en) | 2010-11-23 | 2014-05-13 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
WO2014158528A1 (en) * | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
WO2014165044A1 (en) | 2013-03-13 | 2014-10-09 | Abbvie Inc. | Processes for the preparation of an apoptosis-inducing agent |
US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US9045475B2 (en) | 2009-05-26 | 2015-06-02 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US20150241429A1 (en) * | 2012-09-11 | 2015-08-27 | Hospital For Special Surgery | Irhom2 inhibition for the treatment of complement mediated disorders |
WO2016024230A1 (en) | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, and/or a bcl-2 inhibitor |
US9345702B2 (en) | 2010-11-23 | 2016-05-24 | Abbvie Inc. | Methods of treatment using selective Bcl-2 inhibitors |
WO2017079399A1 (en) | 2015-11-03 | 2017-05-11 | Genentech, Inc. | Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer |
US9814721B2 (en) | 2010-06-03 | 2017-11-14 | Pharmacyclics Llc | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
US9849128B2 (en) | 2014-01-28 | 2017-12-26 | Unity Biotechnology, Inc. | Unit dose of a cis-imidazoline for treating an osteoarthritic joint by removing senescent cells |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
US9884065B2 (en) | 2011-12-13 | 2018-02-06 | Buck Institute For Research On Aging | Inhibiting activity of senescent cells using a glucocorticoid |
US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
US10213433B2 (en) | 2010-10-29 | 2019-02-26 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
EP3626241A4 (en) * | 2017-06-26 | 2020-05-27 | Shenzhen Targetrx, Inc. | N-BENZOLSULFONYLBENZAMIDE COMPOUND FOR INHIBITING BCL-2 PROTEIN AND COMPOSITION AND USE THEREOF |
US10954567B2 (en) | 2012-07-24 | 2021-03-23 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK) |
US11110087B2 (en) | 2012-09-07 | 2021-09-07 | Genentech, Inc. | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
WO2021217051A1 (en) | 2020-04-24 | 2021-10-28 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates |
US11319316B2 (en) | 2016-04-21 | 2022-05-03 | Bioventures, Llc | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof |
US11318134B2 (en) | 2018-01-10 | 2022-05-03 | Recurium Ip Holdings, Llc | Benzamide compounds |
US11369599B2 (en) | 2010-10-29 | 2022-06-28 | Abbvie Inc. | Melt-extruded solid dispersions containing an apoptosis-inducing agent |
US11480568B2 (en) * | 2017-09-28 | 2022-10-25 | Yeda Research And Development Co. Ltd. | Diagnosis of autoimmune diseases |
US11517572B2 (en) | 2014-01-28 | 2022-12-06 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a SRC inhibitor and a flavonoid |
US11897864B2 (en) | 2009-05-26 | 2024-02-13 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
US11980616B2 (en) | 2020-12-07 | 2024-05-14 | Mayo Foundation For Medical Education And Research | Treating liver disease by selectively eliminating senescent cells |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3708170A1 (en) * | 2014-05-05 | 2020-09-16 | BioVentures, LLC | Compositions and methods for inhibiting antiapoptotic bcl-2 proteins as anti-aging agents |
US11666580B2 (en) | 2015-08-10 | 2023-06-06 | Dana-Farber Cancer Institute, Inc. | Mechanism of resistance to bet bromodomain inhibitors |
EP4129999A1 (en) | 2016-08-05 | 2023-02-08 | The Regents Of The University Of Michigan | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
US10285998B1 (en) | 2018-04-04 | 2019-05-14 | The Menopause Method, Inc. | Composition and method to aid in hormone replacement therapy |
KR20210003731A (ko) | 2018-07-31 | 2021-01-12 | 어센테지 파마 (쑤저우) 컴퍼니 리미티드 | Bcl-2 억제제와 MDM2 억제제의 병용 제품 및 질환의 예방 및/또는 치료에 있어서 이의 용도 |
AU2019314819A1 (en) | 2018-07-31 | 2020-10-22 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
CN110772521A (zh) | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
UA125241C2 (uk) | 2018-07-31 | 2022-02-02 | Есентейдж Фарма (Сучжоу) Ко., Лтд. | СИНЕРГІЧНИЙ ПРОТИПУХЛИННИЙ ЕФЕКТ ІНГІБІТОРА Bcl-2 В ПОЄДНАННІ З РИТУКСИМАБОМ ТА/АБО БЕНДАМУСТИНОМ АБО ІНГІБІТОРА Bcl-2 В ПОЄДНАННІ З CHOP |
EP3852766B1 (en) | 2018-09-18 | 2024-05-08 | SignalChem Lifesciences Corporation | Combination therapy for treating blood cancer |
JP7473545B2 (ja) | 2018-10-29 | 2024-04-23 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | トリフルオロメチル置換スルファミド系選択的bcl-2阻害剤 |
US20220220110A1 (en) | 2019-05-24 | 2022-07-14 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Methyl- and trifluoromethyl-containing disubstituted sulfonamide selective bcl-2 inhibitor |
WO2021078301A1 (zh) * | 2019-10-24 | 2021-04-29 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
CN113444078B (zh) * | 2020-03-25 | 2023-07-07 | 中国科学院上海有机化学研究所 | 抗凋亡蛋白Bcl-2抑制剂及其制备方法和应用 |
EP4129998A4 (en) | 2020-04-29 | 2024-05-01 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | CRYSTAL OF A TRIFLUOROMETHYL/CHLORODISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR |
JP2023539114A (ja) * | 2020-08-21 | 2023-09-13 | アセンテージ ファーマ(スーチョウ)カンパニー,リミティド | 全身性エリテマトーデスを治療する組成物及び方法 |
WO2022216942A1 (en) | 2021-04-07 | 2022-10-13 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for the treatment of cancer |
WO2022253313A1 (zh) | 2021-06-04 | 2022-12-08 | 正大天晴药业集团股份有限公司 | 三氟甲基取代的磺酰胺类化合物的磷酸酯 |
IT202100025976A1 (it) | 2021-10-06 | 2023-04-06 | Univ Degli Studi Di Perugia | Combinazione di principi attivi per il trattamento della leucemia acuta mieloide (LAM) con mutazione della nucleofosmina (NPM1) |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2128208A (en) | 1937-02-27 | 1938-08-23 | Du Pont | Alkoxy derivatives of methacrylic acid esters and method of producing them |
MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
FR2736550B1 (fr) | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
DE69631347T2 (de) | 1995-09-15 | 2004-10-07 | Upjohn Co | Aminoaryl oxazolidinone n-oxide |
SI9720020B (en) | 1996-02-09 | 2001-12-31 | Basf Ag | Human antibodies that bind human TNF alpha |
US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
AU767456B2 (en) | 1998-07-06 | 2003-11-13 | Bristol-Myers Squibb Company | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
CA2338328A1 (en) * | 1998-07-21 | 2000-02-03 | Thomas Jefferson University | Small molecule inhibitors of bcl-2 proteins |
DE19913692A1 (de) | 1999-03-25 | 2000-09-28 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
DE19929361A1 (de) | 1999-06-25 | 2001-01-04 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
MXPA02006474A (es) | 1999-12-28 | 2002-11-29 | Eisai Co Ltd | Compuestos heterociclicos que contienen sulfonamida. |
US6720338B2 (en) | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
AR031130A1 (es) | 2000-09-20 | 2003-09-10 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
US20020055631A1 (en) | 2000-09-20 | 2002-05-09 | Augeri David J. | N-acylsulfonamide apoptosis promoters |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
DE60213810T2 (de) | 2001-06-06 | 2007-02-01 | Eli Lilly And Co., Indianapolis | Benzoylsulfonamide und sulfonylbenzamidine zur verwendung als antitumor-mittel |
GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
US20090247613A1 (en) | 2002-02-20 | 2009-10-01 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF B-CELL CLL/LYMPHOMA-2 (BCL2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
MY135609A (en) | 2002-02-26 | 2008-05-30 | Astrazeneca Ab | Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative |
IL163689A0 (en) | 2002-02-26 | 2005-12-18 | Astrazeneca Ab | Novel crystalline forms of the anti-cancer compound zd1839 |
FR2836914B1 (fr) | 2002-03-11 | 2008-03-14 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
TWI262077B (en) | 2002-04-29 | 2006-09-21 | Merck & Co Inc | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
WO2005024636A1 (ja) | 2003-09-04 | 2005-03-17 | Hitachi Ulsi Systems Co., Ltd. | 半導体装置 |
US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
US7642260B2 (en) | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
US7790190B2 (en) | 2004-03-20 | 2010-09-07 | Yasoo Health, Inc. | Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid |
DE602004009344T2 (de) | 2004-04-19 | 2008-07-10 | Symed Labs Ltd., Hyderabad | Neues verfahren zur herstellung von linezolid und verwandten verbindungen |
WO2006008754A1 (en) | 2004-07-20 | 2006-01-26 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
DE602005007048D1 (de) | 2004-08-27 | 2008-07-03 | Bayer Pharmaceuticals Corp | Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs |
WO2006039164A2 (en) | 2004-09-29 | 2006-04-13 | Amr Technology, Inc. | Novel cyclosporin analogues and their pharmaceutical uses |
PT1888550E (pt) | 2005-05-12 | 2014-09-03 | Abbvie Bahamas Ltd | Promotores de apoptose |
US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
US20080300267A1 (en) | 2005-05-16 | 2008-12-04 | Barun Okram | Compounds and Compositions as Protein Kinase Inhibitors |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
BRPI0611863B1 (pt) | 2005-06-22 | 2021-11-23 | Plexxikon, Inc | Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo |
US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
WO2007065167A1 (en) | 2005-12-02 | 2007-06-07 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
EP1880715A1 (en) | 2006-07-19 | 2008-01-23 | Abbott GmbH & Co. KG | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
EP2061560A2 (en) | 2006-09-05 | 2009-05-27 | Abbott Laboratories | Bcl inhibitors for treating platelet excess |
US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
WO2008064116A2 (en) | 2006-11-16 | 2008-05-29 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
KR101335845B1 (ko) | 2007-02-15 | 2013-12-02 | 에프. 호프만-라 로슈 아게 | Taar1 리간드로서의 2-아미노옥사졸린 |
US8536157B2 (en) | 2007-04-13 | 2013-09-17 | The University Of Melbourne | Non-steroidal compounds |
US7528131B2 (en) | 2007-04-19 | 2009-05-05 | Concert Pharmaceuticals Inc. | Substituted morpholinyl compounds |
US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
WO2009035598A1 (en) | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
EP2193127A4 (en) * | 2007-09-27 | 2011-09-14 | Inst Medical W & E Hall | BENZOTHIAZOLE COMPOUNDS |
CA2700999A1 (en) | 2007-10-01 | 2009-04-09 | Arkema Inc. | Blends of biodegradable polymers and acrylic copolymers |
MX2010003548A (es) * | 2007-10-01 | 2010-06-02 | Univ Johns Hopkins | Metodos para el tratamiento de padecimientos neurologicos autoinmunes con ciclofosfamida. |
WO2009045476A1 (en) | 2007-10-02 | 2009-04-09 | Concert Pharmaceuticals, Inc. | Pyrimidinedione derivatives |
US8410124B2 (en) | 2007-10-18 | 2013-04-02 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
WO2009052443A1 (en) * | 2007-10-19 | 2009-04-23 | Burnham Institute For Medical Research | Naphthalene-based inhibitors of anti-apoptotic proteins |
WO2009055006A1 (en) | 2007-10-26 | 2009-04-30 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
NZ601350A (en) | 2007-11-16 | 2013-08-30 | Abbvie Inc | Method of treating arthritis |
US20090149461A1 (en) | 2007-12-06 | 2009-06-11 | Abbott Laboratories | Method of treating cancer |
CN101481363B (zh) * | 2008-01-10 | 2011-05-04 | 江苏豪森药业股份有限公司 | 一种制备瑞格列奈的方法 |
KR20100113112A (ko) | 2008-01-15 | 2010-10-20 | 아보트 러보러터리즈 | 개선된 포유동물 발현 벡터 및 이의 용도 |
WO2009129317A1 (en) * | 2008-04-15 | 2009-10-22 | Burnham Institute For Medical Research | An inhibitor of anti-apoptotic proteins |
HUE030800T2 (en) | 2008-10-07 | 2017-05-29 | Astrazeneca Uk Ltd | Pharmaceutical Form No. 514 |
US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
US8586754B2 (en) * | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
MX2011005922A (es) * | 2008-12-05 | 2011-06-16 | Abbott Lab | Derivados de sulfonamida como agentes inductores de apoptosis selectiva de bcl-2 para el tratamiento del cancer y enfermedades inmunes. |
US20110245156A1 (en) | 2008-12-09 | 2011-10-06 | Cytokine Pharmasciences, Inc. | Novel antiviral compounds, compositions, and methods of use |
WO2010072734A2 (en) | 2008-12-23 | 2010-07-01 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Targeting prodrugs and compositions for the treatment of gastrointestinal diseases |
CN104945311A (zh) | 2009-01-19 | 2015-09-30 | Abbvie公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
RU2539587C2 (ru) | 2009-01-19 | 2015-01-20 | Эббви Инк. | Индуцирующие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний |
US20100297194A1 (en) | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
TWI537269B (zh) | 2009-05-26 | 2016-06-11 | 艾伯維巴哈馬有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘發劑 |
US8546399B2 (en) * | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
TWI540132B (zh) | 2009-06-08 | 2016-07-01 | 亞培公司 | Bcl-2族群抑制劑之口服醫藥劑型 |
TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
EP2632436B1 (en) | 2010-10-29 | 2018-08-29 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
WO2012071374A1 (en) * | 2010-11-23 | 2012-05-31 | Abbott Laboratories | Methods of treatment using selective bcl-2 inhibitors |
US8722657B2 (en) | 2010-11-23 | 2014-05-13 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
-
2011
- 2011-11-22 WO PCT/US2011/061769 patent/WO2012071374A1/en active Application Filing
- 2011-11-22 ES ES11793928.0T patent/ES2603129T3/es active Active
- 2011-11-22 RS RS20161159A patent/RS55545B1/sr unknown
- 2011-11-22 PL PL11793928T patent/PL2642999T3/pl unknown
- 2011-11-22 MY MYPI2017000882A patent/MY191300A/en unknown
- 2011-11-22 HU HUE11793928A patent/HUE031267T2/en unknown
- 2011-11-22 CN CN201180065747.XA patent/CN103402521B/zh not_active Expired - Fee Related
- 2011-11-22 ES ES16153335T patent/ES2701603T3/es active Active
- 2011-11-22 MY MYPI2013700925A patent/MY165884A/en unknown
- 2011-11-22 NZ NZ610746A patent/NZ610746A/en not_active IP Right Cessation
- 2011-11-22 KR KR1020137016217A patent/KR101841084B1/ko active IP Right Grant
- 2011-11-22 BR BR112013012854-2A patent/BR112013012854B1/pt not_active IP Right Cessation
- 2011-11-22 LT LTEP11793928.0T patent/LT2642999T/lt unknown
- 2011-11-22 AR ARP110104338A patent/AR083946A1/es unknown
- 2011-11-22 SG SG2013040167A patent/SG190399A1/en unknown
- 2011-11-22 KR KR1020187007228A patent/KR20180030257A/ko active Application Filing
- 2011-11-22 MX MX2013005849A patent/MX346201B/es active IP Right Grant
- 2011-11-22 RU RU2013128544/14A patent/RU2593231C2/ru active
- 2011-11-22 AU AU2011332000A patent/AU2011332000B2/en not_active Ceased
- 2011-11-22 UY UY0001033746A patent/UY33746A/es not_active Application Discontinuation
- 2011-11-22 NZ NZ708508A patent/NZ708508A/en not_active IP Right Cessation
- 2011-11-22 UA UAA201307893A patent/UA113157C2/uk unknown
- 2011-11-22 EP EP16153335.1A patent/EP3028702B1/en active Active
- 2011-11-22 CN CN201610007260.0A patent/CN105664164B/zh not_active Expired - Fee Related
- 2011-11-22 TW TW100142779A patent/TWI535701B/zh not_active IP Right Cessation
- 2011-11-22 DK DK11793928.0T patent/DK2642999T3/en active
- 2011-11-22 PT PT117939280T patent/PT2642999T/pt unknown
- 2011-11-22 EP EP11793928.0A patent/EP2642999B1/en active Active
- 2011-11-22 CA CA2820618A patent/CA2820618C/en not_active Expired - Fee Related
- 2011-11-22 SG SG10201509631SA patent/SG10201509631SA/en unknown
- 2011-11-22 SI SI201131050A patent/SI2642999T1/sl unknown
- 2011-11-22 KR KR1020197027331A patent/KR20190109590A/ko active Application Filing
- 2011-11-22 TW TW105100832A patent/TWI620736B/zh not_active IP Right Cessation
- 2011-11-22 JP JP2013541010A patent/JP5876067B2/ja not_active Expired - Fee Related
- 2011-11-22 US US13/301,898 patent/US20120129853A1/en not_active Abandoned
- 2011-11-22 UA UAA201607110A patent/UA119150C2/uk unknown
-
2013
- 2013-05-16 ZA ZA2013/03589A patent/ZA201303589B/en unknown
- 2013-05-21 IL IL226490A patent/IL226490A/en active IP Right Grant
- 2013-05-22 CL CL2013001458A patent/CL2013001458A1/es unknown
- 2013-05-22 GT GT201300136A patent/GT201300136A/es unknown
- 2013-06-07 CR CR20130268A patent/CR20130268A/es unknown
- 2013-06-21 EC ECSP13012710 patent/ECSP13012710A/es unknown
-
2014
- 2014-11-06 US US14/535,070 patent/US9345702B2/en active Active
-
2016
- 2016-01-19 JP JP2016007618A patent/JP6215368B2/ja not_active Expired - Fee Related
- 2016-04-22 US US15/136,582 patent/US9872861B2/en active Active
- 2016-05-20 PH PH12016500939A patent/PH12016500939A1/en unknown
- 2016-06-27 AU AU2016204396A patent/AU2016204396B2/en not_active Ceased
- 2016-12-13 CY CY20161101289T patent/CY1118442T1/el unknown
- 2016-12-21 HR HRP20161762TT patent/HRP20161762T1/hr unknown
-
2017
- 2017-03-03 DO DO2017000056A patent/DOP2017000056A/es unknown
- 2017-04-20 IL IL251845A patent/IL251845B/en active IP Right Grant
- 2017-12-12 US US15/838,605 patent/US20180369250A1/en not_active Abandoned
-
2019
- 2019-05-17 US US16/415,515 patent/US20200222413A1/en not_active Abandoned
Cited By (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9045475B2 (en) | 2009-05-26 | 2015-06-02 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US11897864B2 (en) | 2009-05-26 | 2024-02-13 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
US9174982B2 (en) | 2009-05-26 | 2015-11-03 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US10751342B2 (en) | 2010-06-03 | 2020-08-25 | Pharmacyclics Llc | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
US10016435B2 (en) | 2010-06-03 | 2018-07-10 | Pharmacyclics Llc | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
US10004746B2 (en) | 2010-06-03 | 2018-06-26 | Pharmacyclics Llc | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
US10004745B2 (en) | 2010-06-03 | 2018-06-26 | Pharmacyclics Llc | Use of inhibitors of Bruton'S tyrosine kinase (Btk) |
US10653696B2 (en) | 2010-06-03 | 2020-05-19 | Pharmacyclics Llc | Use of inhibitors of bruton's tyrosine kinase (BTK) |
US10478439B2 (en) | 2010-06-03 | 2019-11-19 | Pharmacyclics Llc | Use of inhibitors of bruton's tyrosine kinase (Btk) |
US9814721B2 (en) | 2010-06-03 | 2017-11-14 | Pharmacyclics Llc | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
US11672803B2 (en) | 2010-06-03 | 2023-06-13 | Pharmacyclics Llc | Use of inhibitors of Brutons tyrosine kinase (Btk) |
US10213433B2 (en) | 2010-10-29 | 2019-02-26 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
US11369599B2 (en) | 2010-10-29 | 2022-06-28 | Abbvie Inc. | Melt-extruded solid dispersions containing an apoptosis-inducing agent |
US9345702B2 (en) | 2010-11-23 | 2016-05-24 | Abbvie Inc. | Methods of treatment using selective Bcl-2 inhibitors |
US9840502B2 (en) | 2010-11-23 | 2017-12-12 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
US9872861B2 (en) | 2010-11-23 | 2018-01-23 | Abbvie Inc. | Methods of treatment using selective Bcl-2 inhibitors |
US9238649B2 (en) | 2010-11-23 | 2016-01-19 | Abbvie Inc. | Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide |
US10730873B2 (en) | 2010-11-23 | 2020-08-04 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
US8722657B2 (en) | 2010-11-23 | 2014-05-13 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
US9884065B2 (en) | 2011-12-13 | 2018-02-06 | Buck Institute For Research On Aging | Inhibiting activity of senescent cells using a glucocorticoid |
US10954567B2 (en) | 2012-07-24 | 2021-03-23 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK) |
US11413282B2 (en) | 2012-09-07 | 2022-08-16 | Genentech, Inc. | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
US11110087B2 (en) | 2012-09-07 | 2021-09-07 | Genentech, Inc. | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
US11590128B2 (en) | 2012-09-07 | 2023-02-28 | Genentech, Inc. | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
US20150241429A1 (en) * | 2012-09-11 | 2015-08-27 | Hospital For Special Surgery | Irhom2 inhibition for the treatment of complement mediated disorders |
EP3569588A1 (en) | 2013-03-13 | 2019-11-20 | AbbVie Inc. | Process for preparing a synthetic intermediate useful in the preparation of an apoptosis-inducing agent |
EP3293185A1 (en) | 2013-03-13 | 2018-03-14 | AbbVie Inc. | Processes for the preparation of an apoptosis-inducing agent |
WO2014165044A1 (en) | 2013-03-13 | 2014-10-09 | Abbvie Inc. | Processes for the preparation of an apoptosis-inducing agent |
EP4019491A1 (en) | 2013-03-13 | 2022-06-29 | AbbVie Ireland Unlimited Company | Process for preparing a synthetic intermediate useful in the preparation of an apoptosis-inducing agent |
EP3954687A1 (en) | 2013-03-13 | 2022-02-16 | AbbVie Ireland Unlimited Company | Processes and intermediates useful in the preparation of an apoptosis-inducing agent |
TWI675835B (zh) * | 2013-03-14 | 2019-11-01 | 美商艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
EP3415514A1 (en) * | 2013-03-14 | 2018-12-19 | AbbVie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US10081628B2 (en) | 2013-03-14 | 2018-09-25 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
CN105026394A (zh) * | 2013-03-14 | 2015-11-04 | 艾伯维公司 | 用于治疗癌症和免疫性和自身免疫性疾病的细胞凋亡诱导剂 |
RU2662812C2 (ru) * | 2013-03-14 | 2018-07-31 | Эббви Инк. | Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний |
AU2014242104B2 (en) * | 2013-03-14 | 2018-07-05 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
AU2018226476C1 (en) * | 2013-03-14 | 2020-01-16 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
CN107987075A (zh) * | 2013-03-14 | 2018-05-04 | 艾伯维公司 | 用于治疗癌症和免疫性和自身免疫性疾病的细胞凋亡诱导剂 |
WO2014158528A1 (en) * | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
AU2018226476B2 (en) * | 2013-03-14 | 2019-10-10 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
US9849128B2 (en) | 2014-01-28 | 2017-12-26 | Unity Biotechnology, Inc. | Unit dose of a cis-imidazoline for treating an osteoarthritic joint by removing senescent cells |
US11963957B2 (en) | 2014-01-28 | 2024-04-23 | Mayo Foundation For Medical Education And Research | Treating cardiovascular disease by selectively eliminating senescent cells |
US10478433B2 (en) | 2014-01-28 | 2019-11-19 | Unity Biotechnology, Inc. | Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision loss |
US10413542B2 (en) | 2014-01-28 | 2019-09-17 | Buck Institute For Research On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders using an inhibitor of Akt kinase |
US10517866B2 (en) | 2014-01-28 | 2019-12-31 | Unity Biotechnology, Inc. | Removing senescent cells from a mixed cell population or tissue using a phosphoinositide 3-kinase (PI3K) inhibitor |
US10328073B2 (en) | 2014-01-28 | 2019-06-25 | Unity Biotechnology, Inc. | Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cells |
US10258618B2 (en) | 2014-01-28 | 2019-04-16 | Unity Biotechnology, Inc. | Treating pulmonary conditions by selectively removing senescent cells from the lung using an intermittent dosing regimen |
US10478432B2 (en) | 2014-01-28 | 2019-11-19 | Unity Biotechnology, Inc. | Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eye |
US10213426B2 (en) | 2014-01-28 | 2019-02-26 | Unity Biotechnology, Inc. | Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell population |
US11517572B2 (en) | 2014-01-28 | 2022-12-06 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a SRC inhibitor and a flavonoid |
US10130628B2 (en) | 2014-01-28 | 2018-11-20 | Unity Biotechnology, Inc. | Treatment of joint pain |
US9855266B2 (en) | 2014-01-28 | 2018-01-02 | Unity Biotechnology, Inc. | Treatment for osteoarthritis by intra-articular administration of a cis-imidazoline |
US10010546B2 (en) | 2014-01-28 | 2018-07-03 | Unity Biotechnology, Inc. | Treatment of ophthalmic conditions by selectively removing senescent cells from the eye |
US9980962B2 (en) | 2014-01-28 | 2018-05-29 | Unity Biotechnology, Inc | Use of sulfonamide inhibitors of Bcl-2 to treat senescence-associated lung conditions such as pulmonary fibrosis and chronic obstructive pulmonary disease |
US9993472B2 (en) | 2014-01-28 | 2018-06-12 | Unity Biotechnology, Inc. | Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2 |
US11351167B2 (en) | 2014-01-28 | 2022-06-07 | Buck Institute For Research On Aging | Treating cognitive decline and other neurodegenerative conditions by selectively removing senescent cells from neurological tissue |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
WO2016024230A1 (en) | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, and/or a bcl-2 inhibitor |
US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
US10426788B2 (en) | 2015-03-13 | 2019-10-01 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
US10959993B2 (en) | 2015-11-03 | 2021-03-30 | Genentech, Inc. | Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer |
WO2017079399A1 (en) | 2015-11-03 | 2017-05-11 | Genentech, Inc. | Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer |
US11319316B2 (en) | 2016-04-21 | 2022-05-03 | Bioventures, Llc | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof |
EP3626241A4 (en) * | 2017-06-26 | 2020-05-27 | Shenzhen Targetrx, Inc. | N-BENZOLSULFONYLBENZAMIDE COMPOUND FOR INHIBITING BCL-2 PROTEIN AND COMPOSITION AND USE THEREOF |
US11718611B2 (en) | 2017-06-26 | 2023-08-08 | Shenzhen Targetrx, Inc. | Benzenesulfonylbenazamide compound for inhibiting BCL-2 protein and composition and use thereof |
US11480568B2 (en) * | 2017-09-28 | 2022-10-25 | Yeda Research And Development Co. Ltd. | Diagnosis of autoimmune diseases |
US11318134B2 (en) | 2018-01-10 | 2022-05-03 | Recurium Ip Holdings, Llc | Benzamide compounds |
US11590126B2 (en) | 2018-01-10 | 2023-02-28 | Recurium Ip Holdings, Llc | Benzamide compounds |
US11813260B1 (en) | 2018-01-10 | 2023-11-14 | Recurium Ip Holdings, Llc | Benzamide compounds |
US11813259B2 (en) | 2018-01-10 | 2023-11-14 | Recurium Ip Holdings, Llc | Benzamide compounds |
US11344546B2 (en) | 2018-01-10 | 2022-05-31 | Recurium IP Holding, LLC | Benzamide compounds |
WO2021217051A1 (en) | 2020-04-24 | 2021-10-28 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates |
US11980616B2 (en) | 2020-12-07 | 2024-05-14 | Mayo Foundation For Medical Education And Research | Treating liver disease by selectively eliminating senescent cells |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9872861B2 (en) | Methods of treatment using selective Bcl-2 inhibitors | |
JP2016539927A (ja) | Jak1選択的阻害剤とその使用 | |
US20190314382A1 (en) | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases | |
JP2021524472A (ja) | 乾癬性関節炎の治療方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ABBOTT LABORATORIES, ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ELMORE, STEVEN;SOUERS, ANDREW;WANG, LI CHUN;AND OTHERS;SIGNING DATES FROM 20120103 TO 20120110;REEL/FRAME:027513/0703 |
|
AS | Assignment |
Owner name: ABBVIE INC., ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ABBOTT LABORATORIES;REEL/FRAME:030137/0222 Effective date: 20120801 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |